ATEZOLIZUMAB

BRAND NAME	TECENTRIQ
DRUG CLASS	Non-cytotoxic antineoplastic, monoclonal antibody (humanised)
AVAILABILITY	Vial contains 840 mg/14 mL or 1200 mg/20 mL of atezolizumab. Also contains histidine, glacial acetic acid, sucrose and polysorbate-20.[1] The solution is clear and colourless to slightly yellow.[1]
WARNING	The occupational hazard of intermittent low dose exposure to atezolizumab is not known. Wear a mask and gloves when preparing the infusion solution to minimise exposure. Atezolizumab is not cytotoxic.
pH	5.8[2]
PREPARATION	Dilute the dose with 100 mL or 250 mL of sodium chloride 0.9%. Invert the bag and mix gently. **Do not shake**.[1] The final concentration should be between 3.2 mg/mL and 16.8 mg/mL of atezolizumab.[1]
STABILITY	Vial: store at 2 to 8 °C. Do not freeze. Protect from light.[1] Infusion solution: stable for 8 hours below 25 °C or for 24 hours at 2 to 8 °C.[1]
ADMINISTRATION	
IM injection	Not recommended[1]
SUBCUT injection	Not recommended[1]
IV injection	Not recommended[1]
IV infusion	Infuse the first dose over 60 minutes. If well-tolerated give subsequent infusions over 30 minutes.[1]
COMPATIBILITY	Sodium chloride 0.9%[1]
INCOMPATIBILITY	No information
SPECIAL NOTES	Infusion reactions are common and include chills and pyrexia.[1] For mild or moderate infusion reactions slow the rate of the infusion and monitor carefully. For severe infusion reactions stop the infusion and treat accordingly.[1] Low emetogenic risk.[3] Check your local guidelines for premedication requirements.

REFERENCES

1. Product information. Available from www.tga.gov.au. Accessed 28/01/2021.
2. Tecentriq. US prescribing information. South San Francisco, CA: Genentech Inc. Approved 2016. Updated 30/06/2018. Available from www.dailymed.nlm.nih.gov. Accessed 03/07/2019.
3. Clinical resource: Prevention of antineoplastic induced nausea and vomiting [v4 January 2019]. eviQ [internet]. Sydney: Cancer Institute NSW. Available from www.eviq.org.au. Accessed 10/10/2019.